Poor Survival in Lymphoma Patients Linked to Vitamin D Deficiency

Share this content:

Low levels of vitamin D has been linked to poor prognosis in patients with aggressive lymphoma, according to a new study presented at the American Society of Hematology Annual Meeting and Exposition in New Orleans in December.

According to background information provided by the study's authors, vitamin D has effects on cellular differentiation, proliferation, apoptosis, and angiogenesis. Furthermore, several reports suggest that vitamin D sufficiency is protective against the development of several cancers, including non-Hodgkin lymphoma (NHL). The authors noted that many physicians recommend 800-1200 International Units (IU) of vitamin D daily.

Matthew Drake, MD, PhD, an endocrinologist at Mayo Clinic in Rochester, Minnesota, and colleagues conducted a study that involved 374 newly diagnosed diffuse large B-cell lymphoma patients, half of whom were identified as having a vitamin D deficiency (defined as a total serum 25-O-D less than 25 mg/mL).

Researchers found that vitamin deficiency was associated with inferior overall and event-free survival (defined as progression, retreatment, or death due to any cause). Patients with deficient vitamin D levels had a greater risk of disease progression and risk of dying, compared with patients with sufficient vitamin D levels after accounting for other patient factors associated with worse outcomes.

“The findings support the growing association between vitamin D and cancer risk and outcomes, and suggest that vitamin D supplements might help even those patients already diagnosed with some forms of cancer,” explained Dr. Drake. “The exact roles that vitamin D might play in the initiation or progression of cancer is unknown, but we do know that the vitamin plays a role in regulation of cell growth and death, among other processes important in limiting cancer.”

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs